Life Science News

Dr. Bill Williams President and Chief Executive Officer, BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX: BCT) and his team joined Arne Gulstene Head, TSX Company Services, Toronto Stock Exchange, to celebrate the Company's graduation to Toronto Stock Exchange and open the market.


BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .

For Market Openings: Media may pick up a feed from the TOC (television operations centre) for all market open ceremonies. The feed is named TSX Transmit 1 (SD-SDI) and is produced at the TMX Broadcast Centre and sent live to the TOC. To pick up the feed via the Dejero network, please contact avservices@tmx.com . The client feature video will begin playing on the TMX media wall at approximately 9:27 a.m. ET and the markets will open with the sound of a siren at 9:30 a.m. ET

Date: Thursday February 10 , 2022

Time: 9:00am - 9:30am

Place:  Virtually Broadcast

SOURCE Toronto Stock Exchange

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/10/c0510.html

News Provided by Canada Newswire via QuoteMedia

BCT:CA
BriaCell

BriaCell


Keep reading...Show less
BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

BriaCell Adds Additional Clinical Sites to Broaden Patient Access and Further Boost Enrollment

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, announces that it has activated Hoag Memorial Hospital Presbyterian ("Hoag") and re-engaged Sylvester Comprehensive Cancer Center, part of UHealth the University of Miami Health System, as two additional clinical sites for the screening and enrollment of advanced breast cancer patients in the Phase IIIa combination study of BriaCell's lead candidate, Bria-IMT™, with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat.

"While we continue to steadily accrue patients in our ongoing clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors, the addition of these clinical sites should help further accelerate patient enrollment in the clinical trial. We look forward to discussing our safety and efficacy data with the FDA, now with Fast Track status , to plan our pivotal registration study and remain on track to achieve this major milestone in 2022," stated Dr. Bill Williams, BriaCell's President & CEO.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy

  • U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.
  • Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.
  • BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell's lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer (breast cancer that has spread beyond the breast).

The Fast Track designation will apply to patients with metastatic breast cancer. BriaCell is developing Bria-IMT™ in combination with immune checkpoint inhibitors in a clinical trial listed in ClinicalTrials.gov as NCT03328026 . BriaCell is currently enrolling and dosing advanced breast cancer patients in its Phase I/IIa combination study of Bria-IMT™ with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat under corporate collaboration with Incyte.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research  Annual Meeting 2022

BriaCell Presents Development Details of Bria-OTS Platform Technology at the American Association for Cancer Research Annual Meeting 2022

  • Based on clinical data with Bria-IMT™, BriaCell has developed Bria-OTS™, an off-the-shelf (i.e. pre-manufactured) personalized immunotherapy.
  • Bria-OTS™ will be used to treat patients with advanced breast cancer, providing patients with readily available personalized treatment.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, presented the development details of its novel off-the-shelf (OTS) personalized immunotherapy, Bria-OTS™, summarized in a poster session held at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans, Louisiana.

"Excitement is taking root within BriaCell as we progress towards our upcoming Bria-OTS™ clinical trial, where we will be matching our immunotherapy to each patient's HLA type with the goal of increasing the likelihood of clinical benefit," remarked Dr. Miguel A. Lopez-Lago, Senior Director, R&D. "We intend to treat each patient with a personalized formulation, based on a simple saliva test that determines each patient's HLA types."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
TSXV:BCT

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients.

  • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), a PD-1 inhibitor.
  • Higher levels of immune system activation were directly related to higher incidences of tumor reduction and higher rates of disease control and clinical benefit in patients with advanced breast cancer.

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing the results of clinical studies with its lead product candidate, Bria-IMT™, summarized in a poster session during the SSO 2020 International Conference on Surgical Cancer Care™, a virtual event held in the evenings of August 17-18, 2020. The patient data summarized and discussed belong to previously-disclosed patients (i.e., no incremental numbers enrolled).

Keep reading...Show less
OTC:BCTXF

BriaCell Announces Presentation and Abstract Publication at 2020 American Society of Clinical Oncology (ASCO) Meeting

BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces the publication of its abstract in the ASCO Meeting Library — available in the Journal of Clinical Oncology by May 26, 2020. The Company will present at the 2020 ASCO Annual Meeting, a virtual event held during the dates of the originally planned in-person Annual Meeting (May 29-June 2, 2020). The ASCO Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology.

Dr. Bill Williams, BriaCell’s President & CEO, and Dr. Charles Wiseman, BriaCell’s Scientific Founder and Director, will present clinical data and pathological findings from the Phase I/IIa studies of Bria-IMT™ alone or in combination with checkpoint inhibitors in advanced breast cancer patients.

Keep reading...Show less

LAWSUITS FILED AGAINST AUPH, ARQQ and AMZN - Jakubowitz Law Pursues Shareholders Claims

Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ABBV, SDIG and NTRA

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

ABBVie Inc. (NYSE:ABBV)
Class Period: April 30, 2021 - August 31, 2021
Lead Plaintiff Deadline: June 6, 2022

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Update for Management Cease Trade Order

Naturally Splendid Enterprises Ltd. ("Naturally Splendid" or "NSE" or the "Company" ) (FRANKFURT:50N) (TSX-V:NSP) (OTC:NSPDF) announces an update regarding the application to the British Columbia and Alberta Securities Commission to approve temporary management cease trade order ("MCTO") under National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203"), which, if granted, will prohibit trading securities by the Company by the Chief Executive Officer and Chief Financial Officer of the Corporation until such time as the Required Filings (defined below) and all continuous disclosure requirements have been filed by the Company, and the MCTO has been lifted. During the period in which the MCTO is effective, the general public, who are not insiders of the Company, will continue to be able to trade in the Company's listed securities

The Company has received approval from the British Columbia and Alberta Securities Commission and the Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or about June 30, 2022. The MCTO will be in effect until the Required Filings are filed.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of IBM, MYPS and AUPH

The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff

International Business Machines Corporation (NYSE:IBM)
Class Period: April 4, 2017 - October 20, 2021
Lead Plaintiff Deadline: June 6, 2022

Throughout the class period, International Business Machines Corporation allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Strategic Imperatives Revenue and growth, CAMSS and CAMSS Components' revenue and growth, and the Company's Segments' revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (ii) the Company's present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue and, as a result (iii) the Company misled the market by portraying the Company's Strategic Imperative's financial performance and future prospects more favorable than they actually were as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives.

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less
The Gummy Project

Potent Ventures Announces The Gummy Project Selected by Sweets & Snack Expo Committee to Participate in Power Pitch During Sweets & Snacks Expo

Potent Ventures Inc. (CSE: POT) (FSE: 0OS) (OTCQB: POTVF) ("Potent" or the "Company") is pleased to announce that The Gummy Project is one of two companies selected from the show's Startup Street to participate in Power Pitch at Sweets & Snacks Expo on May 24, 2022.

Power Pitch provides selected companies with an opportunity to showcase their products in a sales pitch-style presentation to a panel of leading US retailers, including the following:

Keep reading...Show less

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ABBV, UPST and AXSM

The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery

ABBVie Inc. (NYSE:ABBV)

News Provided by ACCESSWIRE IA via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×